{"questions": [{"exact_answer": [["neuronal ceroid lipofuscinosis type 2"], ["neuronal ceroid lipofuscinosis type 2 (CLN2)"], ["neuronal ceroid lipofuscinosis type 2 (CLN2) disease"], ["neuronal ceroid lipofuscinosis"], ["neuronal ceroid lipofuscinosis type 2 (CLN2"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c6b810e7c78d6947100002e"}, {"exact_answer": [["DeepVariant"], ["DeepVariant,"], ["DeepVarian"], ["Deep"], ["t"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c51fb7a07ef653866000006"}, {"exact_answer": [["cystic fibrosis"], ["bona fide CF"], ["cystic fibrosis (CF)"], ["bona fide"], ["cystic fibrosis (CF"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c6e16eb7c78d6947100004e"}, {"exact_answer": [["DSMNC"], ["DSMNC:"], ["DSMNC: a database of somatic mutations in normal cells"], ["DS"], ["DSM"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c5b268986df2b9174000019"}, {"exact_answer": [["calcitonin gene-related peptide receptor"], ["the calcitonin gene-related peptide receptor"], ["calcitonin"], ["gene-related peptide receptor"], ["calcitonin gene-related peptide"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c71d7ca7c78d6947100006b"}, {"exact_answer": [["mutations in TGM1"], ["mutations in TGM1."], ["mainly by mutations in TGM1"], ["TGM1"], ["novel mutation of the transglutaminase 1 gene (TGM1)"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c531d8f7e3cb0e231000017"}, {"exact_answer": [["June 2017"], ["2017"], ["in June 2017"], ["June"], ["June 2017 received approval in the USA"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c0117fd133db5eb7800002a"}, {"exact_answer": [["PIK3CA"], ["PIK3CA gene"], ["the PIK3CA"], ["the PIK3CA gene"], ["PIK3"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c5b4a941a4c55d80b000002"}, {"exact_answer": [["ALK G1202R"], ["G1202R"], ["ALK G1202R, the most frequent plasma mutation detected after progression on a second-generation TKI"], ["ALK G1202R, the most frequent plasma mutation detected after progression on a second-generation TKI,"], ["ALK G1202R,"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c72ade07c78d69471000070"}, {"exact_answer": [["Clostridium difficile"], ["C. difficile"], ["recurrent Clostridium difficile"], ["Clostridium difficile,"], ["Clostridium"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c71d6d27c78d6947100006a"}, {"exact_answer": [["CNEFinder"], ["C"], ["CNEFinder;"], ["CNEF"], ["presenting CNEFinder"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c51f01e07ef653866000002"}, {"exact_answer": [["defective activity of \u03b2-hexosaminidase"], ["the defective activity of \u03b2-hexosaminidase"], ["defective activity of \u03b2-hexosaminidase, leading to accumulation of ganglioside GM2"], ["\u03b2-hexosaminidase"], ["a mutation of the \u03b2-subunit gene \u03b2-hexosaminidase B (HexB)"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c78080e7c78d694710000ae"}, {"exact_answer": [["1\u00a0month after hepatectomy."], ["(P\u2009=\u20090.07).Post-hepatectomy"], ["just before and 1\u00a0month after hepatectomy."], ["before and 1\u00a0month after hepatectomy."], ["(P\u2009=\u20090.07).Post-hepatectomy HLs of AFP and DCP are predictors of long-term outcome"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c7839edd774d04240000003"}, {"exact_answer": [["copy number variation-random forest (CNV-RF)"], ["CNV-RF)"], ["copy number variation-random forest (CNV-RF"], ["CNV-RF"], ["copy number variation"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c51f9dd07ef653866000005"}, {"exact_answer": [["by binding to GM1"], ["binding to GM1"], ["by binding to GM1, a monosialoganglioside widely distributed on the plasma membrane surface of various animal epithelial cells"], ["by binding to GM1, a monosialoganglioside widely distributed on the plasma membrane surface"], ["can enter host cells by binding to GM1"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c7813f57c78d694710000b0"}, {"exact_answer": [["mogamulizumab"], ["mogamulizumab,"], ["m"], ["mogamulizumab, a humanized anti-CCR4"], ["mogamulizumab, a humanized anti-CCR4 monoclonal antibody"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c65468ce842deac6700001e"}, {"exact_answer": [["Capillaria hepatica"], ["parasite Capillaria hepatica"], ["parasite"], ["parasite Capillaria hepatica,"], ["the parasite Capillaria hepatica"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c571dd307647bbc4b000016"}, {"exact_answer": [["X-linked hypophosphatemia"], ["XLH"], ["hypophosphatemia"], ["children with X-linked hypophosphatemia"], ["X-linked"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c6b7fb27c78d6947100002d"}, {"exact_answer": [["activation of type I interferons in response to cytosolic nucleic acid ligands"], ["plays an important role in the activation of type I interferons in response to cytosolic nucleic acid ligands"], ["important role in the activation of type I interferons in response to cytosolic nucleic acid ligands"], ["a cytosolic sensor for cyclic dinucleotides"], ["a cytosolic sensor"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c7aae9dd774d0424000000a"}, {"exact_answer": [["PrEP"], ["supplemental indication for Truvada as PrEP"], ["the supplemental indication for Truvada as PrEP"], ["PrEP) and the recent approval by the FDA of the supplemental indication for Truvada as PrEP"], ["Truvada as PrEP"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c5f29a81a4c55d80b00001f"}, {"exact_answer": [["severe rotavirus disease"], ["rotavirus"], ["rotavirus disease"], ["severe rotavirus"], ["severe"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c6e05f37c78d69471000049"}, {"exact_answer": [["tofacitinib"], ["Janus kinase 1"], ["filgotinib"], ["tofaci"], ["tofacitin"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c7039207c78d69471000065"}, {"exact_answer": [["Pilocytic astrocytoma"], ["Pilocytic astrocytoma (PA)"], ["Pilocytic astrocytoma (PA"], ["PA)"], ["Pilocytic astrocytoma (PA) is the most common glioma"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c6bec987c78d69471000033"}, {"exact_answer": [["Periodic leaf-movement"], ["Periodic leaf-movement of legumes"], ["leaf-movement"], ["circadian leaf movement"], ["Period"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c54d1a207647bbc4b000007"}, {"exact_answer": [["heterozygous loss-of-function variants in NFKB1"], ["heterozygous loss-of-function variants"], ["NFKB1"], ["loss-of-function variants in NFKB1"], ["loss-of-function variants"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c629937e842deac67000008"}, {"exact_answer": [["malformations of the eye"], ["the malformations of the eye"], ["malformations of the eye, referring to a congenital absence, and a reduced size of the eyeball"], ["the malformations of the eye, referring to a congenital absence, and a reduced size of the eyeball"], ["malformations of the eye,"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c674c287c78d6947100001a"}, {"exact_answer": [["pembrolizumab"], ["TRK kinases"], ["TRK"], ["LOXO-101), Loxooncology's oral, potent, and selective inhibitor of tropomyosin receptor kinases"], ["potent, and selective inhibitor of tropomyosin receptor kinases (TRK)"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c6e0f537c78d6947100004a"}, {"exact_answer": [["Porphyromonas gingivalis or Treponema denticola"], ["Porphyromonas gingivalis"], ["Treponema denticola"], ["P. gingivalis"], ["spirochetes family and on periodontal pathogens such as Porphyromonas gingivalis"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c53191a7e3cb0e231000016"}, {"exact_answer": [["2.7%"], ["2.7"], ["(2.7%"], ["2.7%)"], ["1 in 38 healthy individuals (2.7%"]], "type": "factoid", "ideal_answer": ["Dummy"], "id": "5c51fe8907ef653866000007"}]}